Last reviewed · How we verify
ICAR19 CAR-T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
ICAR19 CAR-T cells (ICAR19 CAR-T cells) — Immune Cell, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ICAR19 CAR-T cells TARGET | ICAR19 CAR-T cells | Immune Cell, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ICAR19 CAR-T cells CI watch — RSS
- ICAR19 CAR-T cells CI watch — Atom
- ICAR19 CAR-T cells CI watch — JSON
- ICAR19 CAR-T cells alone — RSS
Cite this brief
Drug Landscape (2026). ICAR19 CAR-T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/icar19-car-t-cells. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab